logo
Amgen just got one step closer to bringing its monthly weight loss drug to market

Amgen just got one step closer to bringing its monthly weight loss drug to market

Yahoo05-03-2025

Amgen (AMGN) is getting closer to challenging the weight-loss drug duopoly of Novo Nordisk (NVO), the maker of Ozempic and Wegovy, and Eli Lilly (LLY), which produces Zepbound.
The pharma company announced today that it has begun two late-stage clinical trials for its experimental weight-loss drug, MariTide. If successful, MariTide could disrupt the market by offering a less frequent dosing regimen than the current weekly injections on the market. The drug has been tested as a once-monthly treatment, as well as with dosing intervals of every other month and once every three months.
Amgen's chief scientific officer, Jay Bradner, shared key details of the new trials Wednesday morning at TD Cowen's annual healthcare conference.
The two trials will enroll about 4,500 patients in total. One study will recruit 3,500 participants that are obese or overweight, while the other will include 999 people who are both obese or overweight and have type 2 diabetes.
The primary objective of both studies is to assess the percentage of weight loss at 72 weeks. Amgen will test three dose levels — low, medium, and high — starting patients at a lower dose and gradually increasing it to the target doses. According to ClinicalTrials.gov, the studies are set to begin officially on March 17 and are expected to conclude in early 2027.
In November, the company reported that MariTide helped patients with obesity or excess weight shed an average of 20% of their body weight in an earlier 52-week trial. For comparison, the highest dose of Wegovy resulted in an average weight loss of 15% after 68 weeks in clinical trials. Meanwhile, patients taking the highest dose of Eli Lilly's rival drug, Zepbound, achieved over 20% weight loss after 72 weeks.
For the latest news, Facebook, Twitter and Instagram.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The cheap fat jabs sending big pharma into a frenzy
The cheap fat jabs sending big pharma into a frenzy

Yahoo

time2 hours ago

  • Yahoo

The cheap fat jabs sending big pharma into a frenzy

For many Americans who tuned in to watch the Super Bowl earlier this year, it was a surprise to find themselves fat-shamed during the ad break. 'Obesity is America's deadliest epidemic,' a voiceover said, as images of wobbling bellies, greasy burgers and giant apple pies flashed across TV screens. The Super Bowl's 127m-strong audience, who were tucking into an estimated 1.5bn chicken wings during the event, were warned that 'obesity leads to half a million deaths each year'. But Hims and Hers, the US online medicines company behind the ad, said people should not blame themselves. Instead, its advert claimed that 'the system' was keeping them 'sick and stuck', adding that 'there are medications that work, but they're priced for profits, not patients'. To the relief of viewers, Hims and Hers offered a 'life-changing' solution. Rather than paying hundreds of dollars each month for well-known, branded weight-loss jabs such as Wegovy, households could instead try Hims and Hers' cheaper, replica versions. 'This is the future of healthcare,' it argued. 'Join us in the fight for a healthier America.' However, for the likes of Danish obesity drug maker Novo Nordisk and US pharma rival Eli Lilly, which have claimed the rise of copycat jabs poses potential health risks, such claims have become a serious headache. Over the past few decades, both businesses have poured billions of dollars into obesity drug research – recently yielding blockbuster drugs Wegovy and Mounjaro. The rapid uptake of such drugs has prompted a surge in revenues for big pharma. But bosses are now increasingly worried that demand among American patients has been dented by a cluster of smaller, copycat companies. According to industry estimates from November, around a quarter of the 8m Americans on weight-loss drugs were taking knock-off replica versions. These medicines, known as 'compound' drugs, were priced at around $200 ($148) a month, compared to over $1,300 for some branded versions. Barclays analyst Emily Field says the boom in copycat weight-loss drugs has been a 'unique phenomenon' in the US, sparking an inevitable surge in legal claims that has drawn the attention of regulators. So-called compound drugs are essentially custom-made medicines created by pharmacies using the same active ingredients of patented drugs. Historically, compounding pharmacies create custom versions of medicines if they need to personalise them for patients. For example, if someone is unable to take a standard oral medicine in pill form, or is allergic to an ingredient in an existing medicine. Compounding pharmacies are also typically blocked from mass-producing their drugs. For weight-loss drugs, though, it has been a different story. After the US Food and Drug Administration (FDA) put semaglutide – marketed as the blockbuster obesity drug Wegovy – and tirzepatide – the same for Eli Lilly's Mounjaro – on the shortage list in 2022, compounders were allowed to ramp up production. 'It was almost like these companies found a loophole where they were allowed to do this on a mass scale,' says Field. The impact has been significant. At the start of this year, Novo Nordisk estimated that the copycat drugs accounted for around a third of the entire weight-loss market. That is despite warnings from the FDA about the health risks posed by compounded medicines, which do not have to be approved by the regulator. Beth, from Washington, says she was tempted by online ads for the compound medicines, having struggled with her weight since the pandemic. For her, the drugs helped her at a time when it seemed impossible to lose weight or stick to a diet. She dropped 30lbs over a few months of taking a compound weight-loss medicine. Others say they had little choice but to opt for compound versions, given that the branded medicines were too expensive and not covered by their health insurance. However, the situation is rapidly changing. Last month, the FDA banned mass production of copycat weight-loss treatments that use semaglutide, the ingredient in Novo Nordisk's Wegovy. It also removed tirzepatide from its shortage list last October. Novo Nordisk said the law has now made things clearer. 'Moving forward, any compounder that mass produces or sells knock-off drugs is breaking the law and compromising patient safety,' a spokesman said. Eli Lilly says the products 'pose potentially life-threatening health risks', adding: 'Patients shouldn't be exposed to risky, unapproved products when regulator-approved medicines are available.' Online medicines firms, also known as telehealth businesses, are now racing to find a way to continue getting cheaper, personalised replica drugs out to patients. Noom, a rival to Hims and Hers, has suggested it will still be able to sell compounded weight-loss drugs to patients under an exception set aside for 'personalised' medicines. Hims and Hers, meanwhile, has already struck a new deal with Novo to offer its branded obesity drug to patients. The US firm also said this month it was exploring expansion in the UK, after acquiring European rival Zava. Andrew Dudum, the Hims and Hers chief, suggested there could be 'expansive options in obesity that include that type of personalisation, or similar types', telling the Financial Times that it could sell replica obesity medicines in the UK and Europe. David Meinertz, the boss of Zava, agrees that there are opportunities for the business to grow outside of America. 'There's clearly the experience and expertise that Hims and Hers have built up in the US,' he says. 'But then we have things like the regulatory knowledge here in Zava, and this is where we combine our experiences and spearhead this effort.' Still, the situation in the UK is very different to the US. Here, the compounding pharmacy market is much smaller, with pharmacies able to prepare personalised medicines for patients if it is prescribed by a doctor. Elizabeth Philp, the co-founder of compounding pharmacy Roseway Labs, says there could be a role for more personalisation of medicines. 'The NHS will say wasted medication is one of their top issues – people who try medication, put it in their bathroom cupboard and never use it again because it didn't suit them,' she says. 'We can really help with that.' However, drug insiders argue it would be a 'very bad idea' if the UK started to think about bringing in cheaper compound medicines for weight loss. 'The real drugs are getting very cheap at volumes,' says one senior drug leader. 'Supply is not an issue.' It will be a message that Novo and Eli Lilly will seek to drum home as they seek to prevent smaller rivals from selling cheaper weight-loss medicines to patients. Still, the effects of this debate are already being felt by many in the US battling to lose weight. 'I cannot afford the full price at this time,' says Beth. 'I think it's awful that people are losing access to this medication due to finances or compounded meds going away. 'These drugs are literally life-changing.'

Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue
Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue

Miami Herald

time9 hours ago

  • Miami Herald

Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue

Even the Hamburglar didn't see this one coming. Excessive weight has been a persistent problem in America, where at least one in five adults in each U.S. state is living with obesity, according to the Centers for Disease Control and Prevention. Don't miss the move: Subscribe to TheStreet's free daily newsletter As obesity rates have risen, so have scientists' efforts to address this serious health issue, which can cause asthma, heart disease, stroke, type 2 diabetes and even some cancers. Early attempts to treat obesity came to the market as early as the 1930s. Amphetamines were the prevalent treatment in the 1940s and 1950s and demand continued into the 1990s. Glucagon-like peptide-1 agonists, which mimic the action of the naturally occurring hormone GLP-1, have been available for about two decades. GLP-1 medications, including Ozempic, Wegovy, Zepbound and Mounjaro, have been used for years to treat Type 2 diabetes, and studies have found that they are also effective at encouraging weight loss. Wegovy and Ozempic are manufactured by Novo Nordisk (NVO) , while Eli Lilly (LLY) makes Zepbound and Mounjaro. Image source:One investment firm says increased use of these medications could have serious implications for two of the biggest names in the fast-food industry: McDonald's (MCD) and Domino's Pizza (DPZ) . The market for anti-obesity drugs, particularly those using injectable versions of GLP 1-based drugs, is still new and continuously evolving, Goldman Sachs said in a May 22 report. More Restaurants Beloved Mexican restaurant closing iconic location after 63 yearsMajor restaurant chain quietly closes several locationsIconic restaurant closing its doors after 32 years The investment firm lowered its projections for such medication and now forecasts the global market to reach $95 billion by 2030. That's down from the previous estimate of $130 billion to reflect trends influencing how the drugs are priced, how long patients stay on them, and how patient populations are segmented. Goldman lowered its U.S. market projections to a peak of $70 billion, but the firm sees room for greater penetration in markets outside the U.S. Goldman forecasts a market peak of $50 billion outside the US, compared with $35 billion previously. A survey of more than 50 doctors in the US found that lower doses of anti-obesity medications are working well for a majority of patients and insurance coverage is the most important factor in the decision-making process, Goldman Sachs wrote. "But to be clear, even with this moderated forecast, we see a significant growth opportunity for both existing players as well as new entrants into this market," said Asad Haider, head of the health-care business unit within Goldman Sachs Research. Demand for GPL-1 drugs could dramatically hinder the food and restaurant industries, according to a study from Cornell's SC Johnson College of Business and the data firm Numerator. The report, entitled "The No Hunger Games," found that households with at least one user of GLP-1 drugs reduced its grocery spending by about 6% within six months of starting the drugs. The spending cut was as much as 9% for higher-income households. "We also find an 8.6% decline in spending at fast-food chains, coffee shops and limited-service restaurants," the study said. "Our findings highlight the potential for GLP-1 medications to significantly change food demand, a trend with increasingly important implications for the food industry as GLP-1 adoption continues to grow." The study warned that common side effects of GLP-1 medications, such as nausea, vomiting and gastrointestinal discomfort, have reportedly led to reduced adherence or discontinued use for some patients. Related: McDonald's analyst grills new stock price target on McCrispy reaction "Moreover, their long-term efficacy and safety remain areas of ongoing investigation," the report said. Redburn Atlantic analyst Chris Luyckx focused on the growing adoption of GLP-1 in recent research reports. Luyckx double-downgraded McDonald's to sell from buy with a price target of $260, down from $319. The analyst expects the GLP-1 weight-loss drugs to suppress consumer appetites and says they present an underappreciated longer-term threat for McDonald's. A 1% drag on sales today "could easily build to 10% or more over time," particularly for restaurant brands skewed toward lower-income consumers, the analyst tells investors in a research note. McDonald's stock was down about 1.3% at last check and is up 18.5% from a year ago. Redburn Atlantic also initiated coverage of Domino's Pizza with a sell rating and $340 price target. Domino's, the world's largest pizza chain, faces the heaviest pressure from adoption of GLP-1 weight loss drugs, with high exposure to dinner occasions and lower-income consumers, the firm said. Redburn Atlantic said the company's organic traffic remains weak, with carry-out far outpacing delivery. Challenged system-sales growth and elevated consensus expectations present downside risk for Domino's, the firm said. McDonald's closed regular trading on June 10 down 1.4% at $300.43. Domino's shares were off 2.7% at $455.49. Related: Fund-management veteran skips emotion in investment strategy The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.

What to know about Ozempic: Diabetes drug used off-label for weight loss sparks warnings
What to know about Ozempic: Diabetes drug used off-label for weight loss sparks warnings

Yahoo

time9 hours ago

  • Yahoo

What to know about Ozempic: Diabetes drug used off-label for weight loss sparks warnings

KUALA LUMPUR, June 11 — As global interest in weight loss remedies grows, the off-label use of diabetes medication Ozempic for shedding pounds in non-diabetic individuals has emerged as a trend. This rising popularity, fuelled by social media and anecdotal success stories, has prompted medical professionals to caution against its unsupervised use. Here's what you need to know about Ozempic, its side effects, and why expert supervision is essential before considering it for weight loss. What is Ozempic? Ozempic is a medication primarily approved for managing type 2 diabetes. Its active ingredient, semaglutide, mimics a hormone that targets areas of the brain involved in appetite regulation. Initially designed for diabetes treatment, Ozempic has gained popularity as a weight loss aid, even among non-diabetic individuals. Can Ozempic be used for weight loss? According to Universiti Teknologi MARA consultant endocrinologist Prof Dr Rohana Abdul Ghani, Ozempic is not intended for use as a weight loss medication for non-diabetic patients. 'Ozempic is approved in Malaysia specifically for managing type 2 diabetes. However, semaglutide's weight loss benefits have led some to seek it off-label for obesity treatment,' she said. For non-diabetic patients, semaglutide should be administered at a higher dose of 2.4mg weekly under another brand name, which is unavailable in Malaysia, she added. 'The off-label use of Ozempic among non-diabetic patients has led to a shortage for those with type 2 diabetes and reduced efficacy due to the lower dose,' said Dr Rohana. She also highlighted studies suggesting that regular use of weight loss drugs might establish a 'new normal' in the body, potentially leading to weight gain. One study in the New England Journal of Medicine found that low doses of semaglutide (between 0.25mg and 0.5mg) were linked to weight gain in some patients. What are the potential side effects? As with any medication, Ozempic comes with potential side effects. Dr Rohana said common gastrointestinal side effects include nausea, vomiting, constipation, or diarrhoea, which are typically self-limiting and subside within one to two weeks. She added that rare side effects include skin reactions at the injection site and worsening eyesight, particularly in patients with high blood sugar experiencing rapid improvement. 'Ozempic should not be used by patients with a history of thyroid cancer due to the rare risk of pancreatitis,' she said. Who shouldn't take Ozempic without medical advice? Dr Rohana stressed that no one should take Ozempic without consulting a doctor. 'Medications like Ozempic for obesity should be paired with proper diet and lifestyle changes. Without these, there's a risk of complications such as significant muscle mass loss or kidney issues from severe vomiting,' she said. 'These medications should only be prescribed by clinicians who are familiar with their effects and risks,' she added.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store